{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T20:16:58Z","timestamp":1788034618687,"version":"build-2784847793"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.euf.2026.07.005","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T19:33:00Z","timestamp":1788031980000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncological Outcomes of Robot-assisted PSMA-guided Salvage Surgery in Recurrent Prostate Cancer: Insights from the Prospective TRACE-I Trial"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7392-1626","authenticated-orcid":false,"given":"Lotte G.","family":"Zuur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilda A.","family":"de Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera A.","family":"Ottens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Claire","family":"Berrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias N.","family":"van Oosterom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten L.","family":"Donswijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen J.M.A.","family":"Hendrikx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fijs W.B.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk G.","family":"van der Poel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pim J.","family":"van Leeuwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2026.07.005_b0005","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.07.005_b0010","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.eururo.2018.01.006","article-title":"Efficacy, predictive factors, and prediction nomograms for 68Ga-labeled prostate-specific membrane antigen-ligand positron-emission tomography\/computed tomography in early biochemical recurrent prostate cancer after radical prostatectomy","volume":"73","author":"Rauscher","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.07.005_b0015","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","article-title":"Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study","volume":"395","author":"Hofman","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.euf.2026.07.005_b0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.eururo.2023.10.012","article-title":"The efficacy and safety of metastasis-directed therapy in patients with prostate cancer: a systematic review and meta-analysis of prospective studies","volume":"85","author":"Miszczyk","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.07.005_b0025","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1470-2045(25)00197-4","article-title":"Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial","volume":"26","author":"Ost","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2026.07.005_b0030","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.radonc.2022.10.005","article-title":"Recommendations for radiation therapy in oligometastatic prostate cancer: an ESTRO-ACROP Delphi consensus","volume":"176","author":"Zilli","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.euf.2026.07.005_b0035","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.07.005_b0040","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.eururo.2020.06.043","article-title":"Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: not as good as previously thought","volume":"78","author":"Bravi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.07.005_b0045","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2018.09.009","article-title":"Identifying the optimal candidate for salvage lymph node dissection for nodal recurrence of prostate cancer: results from a large, multi-institutional analysis","volume":"75","author":"Fossati","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.07.005_b0050","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2018.10.041","article-title":"Salvage lymph node dissection for nodal recurrent prostate cancer: a systematic review","volume":"76","author":"Ploussard","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.07.005_b0055","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2967\/jnumed.119.235374","article-title":"Mapping prostate cancer lesions before and after unsuccessful salvage lymph node dissection using repeat PSMA PET","volume":"61","author":"Farolfi","year":"2020","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euf.2026.07.005_b0060","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13550-020-0598-2","article-title":"Results from extended lymphadenectomies with [111In]PSMA-617 for intraoperative detection of PSMA-PET\/CT-positive nodal metastatic prostate cancer","volume":"10","author":"Jilg","year":"2020","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.euf.2026.07.005_b0065","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.eururo.2019.03.045","volume":"76","author":"Horn","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.07.005_b0070","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.eururo.2015.04.034","article-title":"Prostate-specific membrane antigen-radioguided surgery for metastatic lymph nodes in prostate cancer","volume":"68","author":"Maurer","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.07.005_b0075","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.euf.2025.05.019","article-title":"Oncologic outcomes of template versus radioguided salvage lymph node dissection for node-only recurrent prostate cancer on prostate-specific membrane antigen positron emission tomography scan: results from a multi-institutional collaboration","volume":"11","author":"Bravi","year":"2025","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2026.07.005_b0080","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.eururo.2022.03.002","article-title":"Robot-assisted prostate-specific membrane antigen\u2013radioguided salvage surgery in recurrent prostate cancer using a DROP-IN gamma probe: the first prospective feasibility study","volume":"82","author":"de Barros","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.07.005_b0085","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2967\/jnumed.116.178939","article-title":"Preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer","volume":"58","author":"Robu","year":"2017","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euf.2026.07.005_b0090","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s41181-020-00095-9","article-title":"Automated synthesis and quality control of [99mTc]Tc-PSMA for radioguided surgery (in a [68Ga]Ga-PSMA workflow)","volume":"5","author":"Aalbersberg","year":"2020","journal-title":"EJNMMI Radiopharmacy Chem"},{"key":"10.1016\/j.euf.2026.07.005_b0095","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.eururo.2018.03.013","article-title":"99mTechnetium-based prostate-specific membrane antigen\u2013radioguided surgery in recurrent prostate cancer","volume":"75","author":"Maurer","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.07.005_b0100","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.3390\/cancers15205008","article-title":"EAU biochemical recurrence risk classification and PSA kinetics have no value for patient selection in PSMA-radioguided surgery (PSMA-RGS) for oligorecurrent prostate cancer","volume":"15","author":"Falkenbach","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.euf.2026.07.005_b0105","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2022.05.031","article-title":"Cohort study of oligorecurrent prostate cancer patients: oncological outcomes of patients treated with salvage lymph node dissection via prostate-specific membrane antigen\u2013radioguided surgery","volume":"83","author":"Knipper","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.07.005_b0110","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00345-024-05189-6","article-title":"Prostate-specific membrane antigen-radioguided surgery salvage lymph node dissection: experience with fifty oligorecurrent prostate cancer patients","volume":"42","author":"Mayr","year":"2024","journal-title":"World J Urol"},{"key":"10.1016\/j.euf.2026.07.005_b0115","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.euo.2024.04.019","article-title":"Biochemical response of <0.1 ng\/ml predicts therapy-free survival of prostate cancer patients following prostate-specific membrane antigen-targeted salvage surgery","volume":"8","author":"Knipper","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euf.2026.07.005_b0120","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2026.07.005_b0125","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE Phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euf.2026.07.005_b0130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.eururo.2014.08.056","article-title":"Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based Study","volume":"67","author":"Fossati","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.07.005_b0135","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.eururo.2017.09.027","article-title":"Survival outcomes of men with lymph node-positive prostate cancer after radical prostatectomy: a comparative analysis of different postoperative management strategies","volume":"73","author":"Touijer","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2026.07.005_b0140","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.euf.2016.02.018","article-title":"Association between lymph node counts and oncological outcomes in lymph node positive prostate cancer","volume":"3","author":"Mandel","year":"2017","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euf.2026.07.005_b0145","doi-asserted-by":"crossref","first-page":"e348","DOI":"10.1016\/S1470-2045(21)00242-4","article-title":"Elective nodal radiotherapy in prostate cancer","volume":"22","author":"De Meerleer","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2026.07.005_b0150","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41571-022-00655-9","article-title":"The oligometastatic spectrum in the era of improved detection and modern systemic therapy","volume":"19","author":"Katipally","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.euf.2026.07.005_b0155","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2026.07.005_b0160","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41571-018-0119-7","article-title":"Time to abandon single-site irradiation for inducing abscopal effects","volume":"16","author":"Brooks","year":"2019","journal-title":"Nat Rev Clin Oncol"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926001513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456926001513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T19:33:05Z","timestamp":1788031985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456926001513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":32,"alternative-id":["S2405456926001513"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2026.07.005","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncological Outcomes of Robot-assisted PSMA-guided Salvage Surgery in Recurrent Prostate Cancer: Insights from the Prospective TRACE-I Trial","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2026.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}